Laurus Labs spurts as it receives EIR for its Unit 1 & 3 in Vizag
The company, through its filing on BSE, has informed that it has received the Establishment Inspection Report (EIR) from US Food and Drug Administration (US FDA) for its Unit 1&3, located at Parawada, Vishakhapatnam, for the inspection conducted in August 2017.
An EIR is issued when an inspection is completed for an establishment, without the need for an inspectional observation, the establishment is fit to get certified for its intended purpose or business.
USFDA has already cleared Unit 2 of the company in Vizag in September 2017.
Laurus Labs Limited, formerly Laurus Labs Pvt Ltd, is research and development pharmaceutical company. The company is a manufacturer of active pharmaceutical ingredients (APIs) for anti-retroviral (ARV) and Hepatitis C.
The stock is trading at a price of Rs 534, up by 2.05% or Rs 11 on NSE at 9.52 am. The promoters of the company hold 30.56% stake in the company as on September 30, 2017.
Let’s block ads! (Why?)
Via:: Stock – India Infoline